New Research Reports

We maintain our BUY rating on the stock.

We maintain our BUY recommendation on Aurobindo Pharma with a TP of Rs 1,500/share.

Dismal Q4 on continued market share loss in bathware and muted performance of the consumer appliance business

APE and VNB growth slows, expected to normalise going ahead

Retail Research

End of Day Summary

Company is a stainless-steel tubes and pipes manufacturer based in India having over 14 years of experience. Company's products are broadly categorised into: (i) seamless tubes/pipes; and (ii) welded tubes and pipes, under five (5) product lines, namely, (i) stainless steel seamless pipes; (ii) stainless steel seamless tubes; (iii) stainless steel seamless U tubes; (iv) stainless steel instrumentation tubes; and (v) stainless steel welded tubes and U tubes (Products or Stainless Steel Products)....

Standalone revenues stood at Rs. 687 crore, up 2.3% q-o-q/13% y-o-y in line with our estimates of Rs 692 crore. Recruitment business continued to grow, whereas non-recruitment businesses also continued to grow with cash profitability.

Standalone revenue grew by 32% y-o-y to Rs. 8,926 crore while EBITDA was at Rs. 221 crore fell 58% y-o-y. In Q4 Cellulosic Fibre revenue grew by 8% y-o-y While EBITDA de-grew by 36% y-o-y due to increased key input costs.

Colgate’s Q4FY25 performance was muted owing to soft demand in urban markets and heightened competitive intensity. Standalone revenues declined by 1.8% y-o-y to Rs. 1,463 crore, missing our expectation of Rs. 1,520 crore, with toothpaste volumes flat y-o-y.